



1st Half Year 2006 :

A 14% increase in sales Major R&D efforts: ORALAIR® Grasses within sight

The Board of Directors, meeting on 12 September 2006, under the chairmanship of Albert SAPORTA, approved the consolidated financial statements at 30 June 2006, prepared in accordance with international standards. The comparative figures for the first half 2005 have been restated in accordance with these standards.

(€ millions)	2006 1st half year	% of sales	2005 1st half year (restated)	% of sales	06/05 % change
Sales	64.2	100.0	56.1	100.0	+14
Cost of sales	(14.6)	(22.7)	(13.8)	(24.7)	+5
Gross profit	49.6	77.3	42.3	75.3	+17
Other operating expenses	(28.0)	(43.6)	(24.0)	(42.7)	+17
Gross operating profit before R&D	21.6	33.7	18.3	32.6	+18
R&D net	(9.4)	(14.7)	(6.9)	(12.3)	+36
Operating profit	12.2	19.1	11.4	20.3	+7
Net profit	7.7	12.0	7.2	12.8	+7
Earnings per share (diluted)	0.59		0.54		+9
Net borrowings (<i>Gearing</i>)	13.3	(29%)	21.0	(63%)	(37)

The significant improvement in sales and margins financed the development and pre-launch of ORALAIR as well as an ambitious research programme, while maintaining the level of profitability.

Consolidated **sales** for the half year were up 14% (13% organic), due to the high level of new patients.

Gross margin improved by 2 points, through continued productivity gains.

Operating costs were up by 17%, with a major part related to the pre-launch of ORALAIR® Grasses.

Research and Development costs grew by 37% caused by the acceleration of the ORALAIR development programme.

Operating profit and net profit grew by 7%. Net margin represented 12% of sales.

The earnings per share (diluted) increased by 9% and benefited from the share buyback programme carried out in 2005.

Net borrowings were down by 37% in one year to € 13.3 million (gearing of 29%).

Prospects

Growth in the 2nd half year of 2006 will be slower than in the 1st half year. Growth for the full year should be in excess of 10%. The additional resources allocated to ORALAIR should bring profit and borrowings (continued financing of capital expenditure related to the ORALAIR programme) at the end of 2006 to levels approaching those of 2005 in absolute terms. The registration filing of ORALAIR® Grasses in Germany on 13 July 2006 should lead to a launch in Germany in 2007 and in other countries in 2008.

About STALLERGENES

Stallergènes Group is today the world's leading pharmaceutical laboratory specialising in allergen immunotherapy, both in terms of number of patients treated (N°1) and sales (N°2). In its 40 years of existence, Stallergènes has established itself as a dynamic player, frequently as an innovator, in the battle to prevent and cure allergies, rhinitis and asthma in particular. Stallergènes devotes over 15% of its sales to its Research and Development activities. Stallergènes' development is focused on the French market and on international markets through its subsidiaries based in Germany, Spain, Italy, Portugal and Belgium, and its distributors based in Eastern Europe, North Africa and elsewhere.

Shares of the Group's parent company, Stallergènes SA, are listed on the Eurolist Compartment B of the Euronext Paris Stock Exchange.

ISIN Code: FR0000065674

Reuters Code: GEN.PA

Bloomberg Code: GEN.FP



STALLERGENES

Albert SAPORTA – Chairman and CEO
Christian THIRY – Chief Financial Officer
Tél : +33 (0)1 55 59 20 95

PAVIE FINANCE

Lucile de FRAGUIER
Investor & Analyst Relations
Tel: + 33 (0)1 42 15 04 39
contact@pavie-finance.com